Sept 25 (Reuters) - Bristol Myers Squibb ( BMY ) said on
Thursday it will sell its psoriasis drug Sotyktu directly to
cash-paying patients at a more than 80% discount to the drug's
list price.
Bristol will start selling the drug through its BMS Patient
Connect platform from January, the drugmaker said.
Sotyktu is approved to treat moderate-to-severe plaque
psoriasis in adults.